Basic Information
ID: ALA4337960
Type: Binding
Description: Inhibition of N-[2-[(3',6'-dihydroxy-1-oxo-spiro[isobenzofuran-3,9'-xanthene]-5-yl)carbamothioylamino]ethyl]-N'-[6-[4-[5-[[2-(2-pyridyl)acetyl]amino]-1,3,4-thiadiazol-2-yl]butyl]pyridazin-3-yl]pentanediamide binding to human GLS1 expressed in Escherichia coli strain BL21 (DE3)pLysS by fluorescence polarization binding assay
Format: BAO_0000019
Organism: Homo sapiens
Target: Glutaminase kidney isoform, mitochondrial(ALA2146302)
Document: ALA4334507
Inhibition of N-[2-[(3',6'-dihydroxy-1-oxo-spiro[isobenzofuran-3,9'-xanthene]-5-yl)carbamothioylamino]ethyl]-N'-[6-[4-[5-[[2-(2-pyridyl)acetyl]amino]-1,3,4-thiadiazol-2-yl]butyl]pyridazin-3-yl]pentanediamide binding to human GLS1 expressed in Escherichia coli strain BL21 (DE3)pLysS by fluorescence polarization binding assay: 1
Activity Charts
Bioactivity
Activity Types for Assay ALA4337960
IC50
Compound Summary
| Parent Molecular Weight | ALogP | Polar Surface Area |
|---|---|---|
| 524.70 | 4.27 | 4.27 |
| 571.59 | 4.55 | 4.55 |
| 647.79 | 4.36 | 4.36 |
| 617.76 | 4.36 | 4.36 |
| 622.18 | 5.00 | 5.00 |
| 650.69 | 4.70 | 4.70 |
| 642.75 | 3.70 | 3.70 |
| 615.79 | 4.96 | 4.96 |
| 601.76 | 4.66 | 4.66 |
| 610.75 | 4.30 | 4.30 |
| 666.69 | 4.58 | 4.58 |
| 666.63 | 5.11 | 5.11 |
| 615.79 | 4.96 | 4.96 |
| 610.75 | 4.30 | 4.30 |
| 612.72 | 3.69 | 3.69 |
| 587.74 | 4.35 | 4.35 |
| 596.72 | 3.99 | 3.99 |
| 632.73 | 4.26 | 4.26 |
| 612.75 | 4.22 | 4.22 |
| 605.73 | 4.49 | 4.49 |